Home Featured Page 218

Featured

Latest

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s; Veterans’ Views on Psychedelics

A Research Hypothesis, Not A Treatment Recommendation: Marcos Lago on the Viral Psilocybin for Alzheimer’s Case Report

Cybin Announces FDA Investigational New Drug and Institutional Review Board Approvals...

Wesana Health Reports Q3 2021 Financial Results

PT275 – James Fadiman, Ph.D. – Transpersonal Psychology, Microdosing, and Your...

MindMed and Liechti Lab publish first human data on the interacting...

Bright Minds Biosciences Provides Scientific Update on its Novel 5-HT2A Psychedelic...

MYND Life Sciences announces funding for Psilocybin research on Neuroinflammation

Red Light Holland Reports Second Quarter 2021 Results

Numinus Develops Proprietary Psychedelic Tests with New Toxicity and Potency Scans

Albert Labs (CSE: ABRT) Receive Conditional Approval for CSE Listing &...

atai Life Sciences Increases its Ownership Position in COMPASS Pathways

EDITOR PICKS

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s;...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s; Veterans’ Views on Psychedelics

A Research Hypothesis, Not A Treatment Recommendation: Marcos Lago on the Viral Psilocybin for Alzheimer’s Case Report

Psychedelics & Society

Cybin Announces FDA Investigational New Drug and Institutional Review Board Approvals...

Wesana Health Reports Q3 2021 Financial Results

PT275 – James Fadiman, Ph.D. – Transpersonal Psychology, Microdosing, and Your...

MindMed and Liechti Lab publish first human data on the interacting...

Bright Minds Biosciences Provides Scientific Update on its Novel 5-HT2A Psychedelic...

MYND Life Sciences announces funding for Psilocybin research on Neuroinflammation

Red Light Holland Reports Second Quarter 2021 Results

Numinus Develops Proprietary Psychedelic Tests with New Toxicity and Potency Scans

Albert Labs (CSE: ABRT) Receive Conditional Approval for CSE Listing &...

atai Life Sciences Increases its Ownership Position in COMPASS Pathways

EDITOR PICKS

Psychedelic Policy Briefing: Week of June 29nd, 2026

A Country That Recalls Its Own Forgetting

Pα+ Psychedelic Bulletin #226: The Ethics of Psilocybin for Advanced Alzheimer’s;...

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY